Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
Titel:
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
Auteur:
Ridker, Paul M. Amarenco, Pierre Brunell, Robert Glynn, Robert J. Jukema, J. Wouter Kastelein, John J.P. Koenig, Wolfgang Nissen, Steven Revkin, James Santos, Raul D. Schwartz, Pamela F. Yunis, Carla Tardif, Jean-Claude